アルツハイマー病に伴う認知症:治療薬開発パイプライン動向2019

調査会社DelveInsight社が発行したリサーチレポート(データ管理コード:DIPR2016167)
◆英語タイトル:Dementia Associated With Alzheimer's Disease-Pipeline Insights, 2019
◆発行会社/調査会社:DelveInsight
◆商品コード:DIPR2016167
◆発行日:2019年版(※最新版はお問い合わせください)
◆調査対象地域:グローバル
◆産業分野:製薬
◆ページ数:約60
◆レポート言語:英語
◆レポート形式:PDF
◆納品方式:Eメール(受注後3営業日)
◆販売価格オプション(消費税別)
Single User(1名使用)USD1,250 ⇒換算¥142,500見積依頼/購入/質問フォーム
Site Price(同一国内共有可)USD2,500 ⇒換算¥285,000見積依頼/購入/質問フォーム
Enterprise Price(複数国内共有可)USD4,000 ⇒換算¥456,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
DelveInsight社の概要及び新刊レポートはこちらでご確認いただけます。

★グローバルリサーチ資料[アルツハイマー病に伴う認知症:治療薬開発パイプライン動向2019]についてメールでお問い合わせはこちら
※本調査レポートでは、世界におけるアルツハイマー病に伴う認知症の治療薬開発パイプライン動向について調査・分析し、企業別開発中の治療薬、各臨床試験段階における製品リスト及び比較分析、薬剤候補のプロファイル、治療薬の評価、開発中止又は開発休止中の薬剤リスト等をお届けしています。また、アルツハイマー病に伴う認知症治療薬開発に取り組んでいる企業情報も提供しています。

・アルツハイマー病に伴う認知症の概要

・アルツハイマー病に伴う認知症の治療薬パイプライン概要

・企業別開発中のアルツハイマー病に伴う認知症治療薬

・後期治験段階の薬剤(Filed & Phase III):比較分析

・中期治験段階の薬剤(Phase II):比較分析

・初期治験段階の薬剤(Phase I & IND Filed):比較分析

・前臨床段階の薬剤:比較分析

・薬剤候補のプロファイル

・アルツハイマー病に伴う認知症治療薬の評価
  - 単剤治療薬別評価
  - 併用治療薬別評価
  - 投与経路別評価
  - 分子種類別評価

・開発が中止された薬剤リスト

・開発休止中の薬剤リスト

・アルツハイマー病に伴う認知症治療薬開発に取り組んでいる企業リスト

・図表一覧
*** レポート概要(サマリー)***

SUMMARY
DelveInsight’s, “ Dementia Associated With Alzheimer’s Disease-Pipeline Insights, 2019”, report provides in depth insights on the pipeline drugs and their development activities around the Dementia Associated With Alzheimer’s Disease. The DelveInsight’sReport covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details. DelveInsight’s Report also provides detailed information on the discontinued and dormant drugs that have gone inactive over the years for Dementia Associated With Alzheimer’s Disease. DelveInsight’s Report also assesses the Dementia Associated With Alzheimer’s Disease therapeutics by Monotherapy, Combination products, Molecule type and Route of Administration.

Please note:This report requires certain updates. We have all the information available but require 3 business days to complete the process and ensure it is as up-to-date as possible. Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated indication.


Scope
• The report provides competitivepipeline landscape of Dementia Associated With Alzheimer's Disease
• The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information
• Coverage of the Dementia Associated With Alzheimer's Disease pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
• The report reviews key players involved in the therapeutics development for Dementia Associated With Alzheimer's Disease and also provide company profiling
• The report also gives the information of dormant and discontinued pipeline projects
• Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages
• Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type


*** レポート目次(コンテンツ)***

Table of Contents
• Dementia Associated With Alzheimer’s Disease Overview
• Dementia Associated With Alzheimer’s Disease Pipeline Therapeutics
• Dementia Associated With Alzheimer’s Disease Therapeutics under Development by Companies
• Dementia Associated With Alzheimer’s Disease Filed and Phase III Products
• Comparative Analysis
• Dementia Associated With Alzheimer’s Disease Phase II Products
• Comparative Analysis
• Dementia Associated With Alzheimer’s Disease Phase I and IND Filed Products
• Comparative Analysis
• Dementia Associated With Alzheimer’s Disease Discovery and Pre-Clinical Stage Products
• Comparative Analysis
• Drug Candidate Profiles
• Dementia Associated With Alzheimer’s Disease – Therapeutics Assessment
• Assessment by Monotherapy Products
• Assessment by Combination Products
• Assessment by Route of Administration
• Assessment by Molecule Type
• Dementia Associated With Alzheimer’s Disease – Discontinued Products
• Dementia Associated With Alzheimer’s Disease – Dormant Products
• Companies Involved in Therapeutics Development for Dementia Associated With Alzheimer’s Disease
• Appendix
• Methodology
• Contact Us
• Disclaimer

List of Tables
• Number of Products under Development for Dementia Associated With Alzheimer's Disease, 2019
• Number of Products under Development by Companies
• Comparative Analysis by Filed and Phase III Products, 2019
• Comparative Analysis Phase II Products, 2019
• Comparative Analysis Phase I and IND Filed Products, 2019
• Comparative Analysis Discovery and Pre-Clinical Stage Products, 2019
• Drug Candidates Profiles
• Dementia Associated With Alzheimer's Disease Assessment by Monotherapy Products
• Dementia Associated With Alzheimer's Disease Assessment by Combination Products
• Dementia Associated With Alzheimer's Disease Assessment by Route of Administration
• Dementia Associated With Alzheimer's Disease Assessment by Stage and Route of Administration
• Dementia Associated With Alzheimer's Disease Assessment by Molecule Type
• Dementia Associated With Alzheimer's Disease Assessment by Stage and Molecule Type
• Dementia Associated With Alzheimer's Disease Therapeutics – Discontinued Products
• Dementia Associated With Alzheimer's Disease Therapeutics – Dormant Products
• Products under Development by Companies, 2019


List of Figures
• Number of Products under Development for Dementia Associated With Alzheimer's Disease, 2019
• Filed and Phase III Products, 2019
• Phase II Products, 2019
• Phase I and IND Filed Products, 2019
• Discovery and Pre-Clinical Stage Products, 2019
• Dementia Associated With Alzheimer's Disease Assessment by Monotherapy Products
• Dementia Associated With Alzheimer's Disease Assessment by Combination Products
• Dementia Associated With Alzheimer's Disease Assessment by Route of Administration
• Dementia Associated With Alzheimer's Disease Assessment by Stage and Route of Administration
• Dementia Associated With Alzheimer's Disease Assessment by Molecule Type
• Dementia Associated With Alzheimer's Disease Assessment by Stage and Molecule Type


*** レポートのキーワード ***

アルツハイマー病に伴う認知症、治療薬、医薬品、薬剤、製薬企業、研究開発、治験、パイプライン

*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/


※おすすめ調査資料
  • 世界の病院情報システム(HIS)市場予測2021年-2026年
    The global hospital information system market reached a value of US$ 115 Billion in 2020. Looking forward, IMARC Group expects the market to grow at a CAGR of 8.4% during 2021-2026. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the i …
  • 廃棄物エネルギー回収の世界市場:技術別(熱的回収、バイオ技術)
    The global waste to energy market was valued at $32,567 million in 2016, and is projected to reach at $54,179 million by 2023, growing at a CAGR of 7.6% from 2017 to 2023. Waste-to-energy also abbreviated as WtE or energy-from-waste EfW is a process of energy recovery and the technique of generating …
  • ドローワイヤポジションセンサの世界市場:販売動向2017
    Notes:Sales, means the sales volume of Draw Wire Position Sensors Revenue, means the sales value of Draw Wire Position Sensors This report studies sales (consumption) of Draw Wire Position Sensors in Global market, especially in United States, China, Europe and Japan, focuses on top players in these …
  • 世界の自動車用アクセルペダル市場2017
    Notes:Sales, means the sales volume of Automotive Accelerator Pedal Revenue, means the sales value of Automotive Accelerator Pedal This report studies sales (consumption) of Automotive Accelerator Pedal in Global market, especially in United States, China, Europe and Japan, focuses on top players in …
  • スマート変圧器のアジア太平洋市場
    KEY FINDINGSThe Asia Pacific smart transformers market was valued at $498 million in 2016 and is expected to reach $2659 million by 2025 growing at a CAGR of 20.53% during the forecast period of 2017-2025. Increasing urbanization and the subsequent increase in electricity demand are majorly responsi …
  • 広告の日本市場
    Advertising in Japan Summary Advertising in Japan industry profile provides top-line qualitative and quantitative summary information including: market size (value 2012-16, and forecast to 2021). The profile also contains descriptions of the leading players including key financial metrics and analys …
  • 骨肉腫(Osteosarcoma):治療薬開発パイプライン動向2019
    SUMMARY DelveInsight’s, “ Osteosarcoma-Pipeline Insights, 2019”, report provides in depth insights on the pipeline drugs and their development activities around the Osteosarcoma. The DelveInsight’sReport covers the product profiles in various stages of development including Discovery, Pre-clinical, …
  • ステビアの世界市場
    About SteviaStevia, also known as stevia rebaudiana, is a natural and calorie-free plant-derived sweetener used as a sugar substitute in food, beverages, and other applications. The stevia plant contains steviol glycosides and is 250-300 times sweeter than sugar. Technavio’s analysts forecast the gl …
  • 世界のデジタルオシロスコープ市場2017
    Digital Oscilloscope Report by Material, Application, and Geography – Global Forecast to 2021 is a professional and in-depth research report on the world's major regional market conditions, focusing on the main regions (North America, Europe and Asia-Pacific) and the main countries (United States, G …
  • 2-メチル-プロペン酸の世界市場予測2019-2024
    This colorless, viscous liquid is a carboxylic acid with an acrid unpleasant odor. It is soluble in warm water and miscible with most organic solvents. According to this study, over the next five years the 2-Methyl-Propenoic Acid market will register a xx% CAGR in terms of revenue, the global market …
※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
※当市場調査資料(DIPR2016167 )"アルツハイマー病に伴う認知症:治療薬開発パイプライン動向2019" (英文:Dementia Associated With Alzheimer's Disease-Pipeline Insights, 2019)はDelveInsight社が調査・発行しており、H&Iグローバルリサーチが販売します。


◆H&Iグローバルリサーチのお客様(例)◆


※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
※H&Iグローバルリサーチ(登録第5864124号)及びH&I(登録第5783645号)はH&Iグローバルリサーチ株式会社の商標です。